74.59 USD
-0.35 (-0.47%)
74.59 USD
0 (0%)
Overall PTCT gets a fundamental rating of 5 out of 10. We evaluated PTCT against 529 industry peers in the Biotechnology industry. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here. PTCT is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make PTCT suitable for growth investing!
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
PTCT had a positive operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 28.43%, PTCT belongs to the top of the industry, outperforming 97.73% of the companies in the same industry.
PTCT has a better Return On Invested Capital (41.48%) than 99.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROIC | 41.48% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTCT's Profit Margin of 42.25% is amongst the best of the industry. PTCT outperforms 97.54% of its industry peers.
PTCT has a better Operating Margin (52.45%) than 99.62% of its industry peers.
The Gross Margin of PTCT (96.83%) is better than 96.60% of its industry peers.
PTCT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
The number of shares outstanding for PTCT has been increased compared to 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.15 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.15, PTCT is in the better half of the industry, outperforming 65.97% of the companies in the same industry.
The Debt to FCF ratio of PTCT is 3.38, which is a good value as it means it would take PTCT, 3.38 years of fcf income to pay off all of its debts.
PTCT has a Debt to FCF ratio of 3.38. This is amongst the best in the industry. PTCT outperforms 92.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Altman-Z | 2.15 |
ROIC/WACC5.76
WACC7.2%
2.3 Liquidity
A Current Ratio of 2.32 indicates that PTCT has no problem at all paying its short term obligations.
The Current ratio of PTCT (2.32) is worse than 73.35% of its industry peers.
A Quick Ratio of 2.26 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a worse Quick ratio (2.26) than 72.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 277.07% over the past year.
Looking at the last year, PTCT shows a very strong growth in Revenue. The Revenue has grown by 97.54%.
The Revenue has been growing by 21.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
3.2 Future
Based on estimates for the next years, PTCT will show a very strong growth in Earnings Per Share. The EPS will grow by 25.49% on average per year.
The Revenue is expected to grow by 17.10% on average over the next years. This is quite good.
EPS Next Y257.65%
EPS Next 2Y36.69%
EPS Next 3Y30.18%
EPS Next 5Y25.49%
Revenue Next Year122.5%
Revenue Next 2Y10.13%
Revenue Next 3Y13.86%
Revenue Next 5Y17.1%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.27, the valuation of PTCT can be described as reasonable.
Based on the Price/Earnings ratio, PTCT is valued cheaply inside the industry as 97.35% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.26. PTCT is valued rather cheaply when compared to this.
PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 98.49% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaply inside the industry as 98.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.49 | ||
| EV/EBITDA | 5.9 |
4.3 Compensation for Growth
PTCT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 30.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y36.69%
EPS Next 3Y30.18%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
74.59
-0.35 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.01%
Inst Owner Change-0.57%
Ins Owners0.68%
Ins Owner Change4.17%
Market Cap5.99B
Revenue(TTM)1.78B
Net Income(TTM)751.72M
Analysts79.09
Price Target83.37 (11.77%)
Short Float %16.43%
Short Ratio8.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.83%
Min EPS beat(2)23.33%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)1164.83%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)562.98%
EPS beat(12)5
Avg EPS beat(12)357.38%
EPS beat(16)5
Avg EPS beat(16)260.9%
Revenue beat(2)2
Avg Revenue beat(2)7.12%
Min Revenue beat(2)2.58%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)147.37%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)76.88%
Revenue beat(12)7
Avg Revenue beat(12)50.21%
Revenue beat(16)10
Avg Revenue beat(16)38.94%
PT rev (1m)19.73%
PT rev (3m)22.72%
EPS NQ rev (1m)12.21%
EPS NQ rev (3m)40.44%
EPS NY rev (1m)25.73%
EPS NY rev (3m)23.6%
Revenue NQ rev (1m)0.57%
Revenue NQ rev (3m)17.55%
Revenue NY rev (1m)4.24%
Revenue NY rev (3m)3.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | N/A | ||
| P/S | 3.37 | ||
| P/FCF | 8.49 | ||
| P/OCF | 8.37 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.9 |
EPS(TTM)7.26
EY9.73%
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)8.78
FCFY11.78%
OCF(TTM)8.91
OCFY11.95%
SpS22.16
BVpS-1.94
TBVpS-7.9
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROCE | 52.5% | ||
| ROIC | 41.48% | ||
| ROICexc | 822.48% | ||
| ROICexgc | N/A | ||
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% | ||
| FCFM | 39.64% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score7
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Debt/EBITDA | 1.9 | ||
| Cap/Depr | 31.38% | ||
| Cap/Sales | 0.58% | ||
| Interest Coverage | 163.67 | ||
| Cash Conversion | 74.07% | ||
| Profit Quality | 93.81% | ||
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.15 |
F-Score7
WACC7.2%
ROIC/WACC5.76
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
EPS Next Y257.65%
EPS Next 2Y36.69%
EPS Next 3Y30.18%
EPS Next 5Y25.49%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
Revenue Next Year122.5%
Revenue Next 2Y10.13%
Revenue Next 3Y13.86%
Revenue Next 5Y17.1%
EBIT growth 1Y813.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year785.26%
EBIT Next 3Y60.78%
EBIT Next 5YN/A
FCF growth 1Y375.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.28%
OCF growth 3YN/A
OCF growth 5YN/A
PTC THERAPEUTICS INC / PTCT FAQ
What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PTCT.
Can you provide the valuation status for PTC THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.
Can you provide the profitability details for PTC THERAPEUTICS INC?
PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.
What are the PE and PB ratios of PTC THERAPEUTICS INC (PTCT) stock?
The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 10.27 and the Price/Book (PB) ratio is -38.45.